AR024771A1 - Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes - Google Patents

Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes

Info

Publication number
AR024771A1
AR024771A1 ARP000103659A ARP000103659A AR024771A1 AR 024771 A1 AR024771 A1 AR 024771A1 AR P000103659 A ARP000103659 A AR P000103659A AR P000103659 A ARP000103659 A AR P000103659A AR 024771 A1 AR024771 A1 AR 024771A1
Authority
AR
Argentina
Prior art keywords
vaccines
against feline
sequence
particular recombinant
feline calicivirosis
Prior art date
Application number
ARP000103659A
Other languages
English (en)
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9909421A external-priority patent/FR2796396A1/fr
Application filed by Merial Sas filed Critical Merial Sas
Publication of AR024771A1 publication Critical patent/AR024771A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Secuencia del gen de la cápside y secuencia de cDNA correspondiente, de una cepa FCV dominante denominada FCV 431. Secuencia del gen de la cápside y secuencia del cDNA de una cepa complementaria denominada G1. Las secuencias del cDNA pueden ser incorporadas a vectores de expresion para la preparacion depreparados inmunogénicos y de vacunas de subunidades o recombinantes que permiten la vacunacion contra la calicivirosis felina.
ARP000103659A 1999-07-16 2000-07-17 Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes AR024771A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9909421A FR2796396A1 (fr) 1999-07-16 1999-07-16 Gene de calicivirus felin et vaccin recombine les incorporant
FR0001761A FR2796397B1 (fr) 1999-07-16 2000-02-11 Genes de calicivirus felin et vaccins notamment vaccins recombines

Publications (1)

Publication Number Publication Date
AR024771A1 true AR024771A1 (es) 2002-10-23

Family

ID=26212169

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103659A AR024771A1 (es) 1999-07-16 2000-07-17 Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes

Country Status (18)

Country Link
EP (1) EP1228193B1 (es)
JP (1) JP2003515315A (es)
KR (1) KR100805807B1 (es)
AR (1) AR024771A1 (es)
AT (1) ATE384118T1 (es)
AU (1) AU6576500A (es)
BR (1) BR0012512B1 (es)
CA (1) CA2379539C (es)
DE (1) DE60037826T2 (es)
DK (1) DK1228193T3 (es)
ES (1) ES2302496T3 (es)
FR (1) FR2796397B1 (es)
HU (1) HU228708B1 (es)
MX (1) MXPA02000464A (es)
PL (1) PL203842B1 (es)
PT (1) PT1228193E (es)
TW (2) TWI295322B (es)
WO (1) WO2001005934A2 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
FR2830535B1 (fr) 2001-10-10 2003-12-19 Commissariat Energie Atomique Utilisation d'acides sulfoniques, phosphoniques comme dopants de la polyaniline et de materiaux composites conducteurs a base de polyaniline
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
ES2417019T3 (es) 2003-11-13 2013-08-05 University Of Georgia Research Foundation, Inc. Procedimiento de caracterización del virus de la enfermedad de la bursitis infecciosa
CN101208104B (zh) 2005-04-25 2012-10-31 梅瑞尔有限公司 Nipah病毒疫苗
CA2617341C (en) * 2005-07-28 2011-03-29 Pfizer Products Inc. Methods of vaccine administration, new feline caliciviruses, and treatments for immunizing animals against feline paraovirus and feline herpes virus
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
JP2009515529A (ja) 2005-11-14 2009-04-16 メリアル リミテッド 腎不全のための遺伝子療法
EP3167900B1 (en) 2006-03-29 2018-11-21 Merial Limited Vaccine against streptococci
ES2760004T3 (es) 2008-05-08 2020-05-12 Boehringer Ingelheim Animal Health Usa Inc Vacuna contra Leishmania utilizando un inmunnógeno salival de mosca de la arena
US9592213B2 (en) 2009-06-17 2017-03-14 National University Corporation Kumamoto University Prophylactic and/or therapeutic agent for dysmenorrhea
US9216213B2 (en) 2011-04-20 2015-12-22 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
CA2837375C (en) 2011-06-01 2019-07-16 Merial Limited Needle-free administration of prrsv vaccines
CN103957932B (zh) 2011-07-20 2017-06-23 梅里亚有限公司 包含最优化的猫白血病病毒包膜基因的重组猫白血病病毒疫苗
SI2741740T1 (sl) 2011-08-12 2017-08-31 Merial, Inc. Vakuumsko konzerviranje bioloških proizvodov, zlasti cepiv
AU2013235423B2 (en) 2012-03-20 2017-03-30 Boehringer Ingelheim Animal Health USA Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein C and uses thereof
EP3215188A1 (en) 2014-11-03 2017-09-13 Merial, Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
WO2019068905A2 (en) 2017-10-06 2019-04-11 Virbac FELINE VACCINES CONFERRING EARLY PROTECTION

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
DE69032284T2 (de) * 1989-03-21 1998-10-08 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
EP0484382B1 (en) * 1989-07-21 1995-03-08 The Upjohn Company Feline calicivirus capsid protein and nucleotide sequence
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
NZ309945A (en) * 1995-05-23 2001-04-27 Univ California Abundant extracellular products and their use as vaccines
US5858373A (en) * 1995-12-01 1999-01-12 Virogenetics Corporation Recombinant poxvirus-feline infectious peritionitis virus, compositions thereof and methods for making and using them
ZA97452B (en) * 1996-01-25 1997-08-15 Trinity College Dublin Streptococcus equi vaccine.
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
US5861397A (en) * 1996-10-03 1999-01-19 Vical Incorporated Piperazine based cytofectins
US7255862B1 (en) * 1996-11-14 2007-08-14 Connaught Technology Corporation ALVAC/FIV constructs
US6231863B1 (en) * 1997-06-10 2001-05-15 American Cyanamid Company DNA sequences, molecules, vectors and vaccines for feline calicivirus disease and methods for producing and using same
US6291423B1 (en) * 1997-06-12 2001-09-18 Transgene S.A. Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapy

Also Published As

Publication number Publication date
TWI316089B (en) 2009-10-21
ES2302496T3 (es) 2008-07-16
DE60037826D1 (de) 2008-03-06
EP1228193B1 (fr) 2008-01-16
WO2001005934A2 (fr) 2001-01-25
BR0012512A (pt) 2002-04-02
JP2003515315A (ja) 2003-05-07
EP1228193A2 (fr) 2002-08-07
CA2379539A1 (en) 2001-01-25
FR2796397B1 (fr) 2006-09-01
KR20020015378A (ko) 2002-02-27
AU6576500A (en) 2001-02-05
MXPA02000464A (es) 2002-07-30
DK1228193T3 (da) 2008-05-26
HU228708B1 (en) 2013-05-28
ATE384118T1 (de) 2008-02-15
WO2001005934A3 (fr) 2001-04-26
CA2379539C (en) 2012-01-03
KR100805807B1 (ko) 2008-02-21
DE60037826T2 (de) 2009-03-05
TWI295322B (en) 2008-04-01
PL352462A1 (en) 2003-08-25
PT1228193E (pt) 2008-04-28
TW200813221A (en) 2008-03-16
HUP0202385A2 (en) 2002-10-28
FR2796397A1 (fr) 2001-01-19
BR0012512B1 (pt) 2011-05-17
HUP0202385A3 (en) 2004-07-28
PL203842B1 (pl) 2009-11-30

Similar Documents

Publication Publication Date Title
AR024771A1 (es) Genes y vacunas efectivas contra la calicivirosis felina, en particular vacunas recombinantes
ATE526411T1 (de) Avirulente, immunogene flavivirus-chimäre
IL164318A0 (en) Recombinant mva virus and vaccine comprising said virus
ES2153223T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
ES2103928T3 (es) Polipeptidos de mycobacterium y acidos nucleicos que los codifican utilizados en el diagnostico y el tratamiento de la tuberculosis.
NO20015073L (no) Vaksiner
ES2070866T3 (es) Vacunas recombinantes contra la coccidiosis.
WO2003091401A3 (en) Multi plasmid system for the production of influenza virus
WO2003048184A3 (en) Flavivirus ns1 subunit vaccine
ATE237682T1 (de) Universale spenderzellen
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
DK1154791T3 (da) Neisseria-vaccinesammensætninger og fremgangsmåder
MXPA02005506A (es) Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo.
EP1439856A4 (en) RECOMBINANT TOLLWOOD VACCINES AND METHOD FOR THEIR PREPARATION AND USE
BR0208532A (pt) Vacina contra leishmania
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
ES2062990T3 (es) Vacunas, que contienen la proteina f del virus del sida.
AU2018200081B2 (en) Avirulent, immunogenic flavivirus chimeras
WO2002055104A3 (en) Acne vaccine
EP1316319A4 (en) NOVEL GENE THERAPY AGENT FOR TREATING HEMOPHILIA B AND METHOD FOR PREPARING THE SAME
WO2000037649A3 (en) Dna vaccine against infectious bursal disease virus
CN214180634U (zh) 一种用于意向再植的专用牙钳
FR2825280B1 (fr) Vaccination contre le virus de l'immunodeficience feline
PT1194450E (pt) Vacina inactivada contra a calicivirose felina
Charles Vaccines against Covid-19, Different Strategies towards the same Goal: Medicinal Chemistry & Chemical Biology Highlights

Legal Events

Date Code Title Description
FG Grant, registration